Scientists seek to engineer mice to curb Lyme disease on Nantucket

On Nantucket, scientists are betting that the best way to fight Lyme disease is to rewrite the mice. Their idea is to release genetically altered wild mice, especially the white-footed mouse, so the animals become immune to Borrelia burgdorferi and stop passing the bacterium to feeding ticks.

The island is a tightly bounded test case. Nantucket sits about 30 miles off Cape Cod and measures roughly 14 miles by 3 miles, which makes it easier to imagine tracking an intervention than on the mainland. CBS News reported that Lyme disease has afflicted 15% of Nantucket residents, a toll that helps explain why local debate has centered on whether the island should become the first place to try what researchers describe as an ecological disease-prevention strategy. MIT researchers presented the proposal to residents in October 2024, and the discussion has since widened beyond science into questions of consent, oversight and whether a community can agree to alter wild populations in place.

The public-health case for trying is straightforward. Lyme disease is transmitted through the bite of infected blacklegged ticks, but the white-footed mouse, Peromyscus leucopus, is a key reservoir host for the bacterium. If mice cannot carry the pathogen, fewer ticks may acquire it, which could reduce the number of infected ticks in the environment. That approach shifts the focus away from deer or tick control alone and toward the reservoir that keeps the cycle going.

The burden is not confined to one island. The Centers for Disease Control and Prevention reported more than 89,000 Lyme disease cases in the United States in 2023 and estimates that about 476,000 people may be diagnosed and treated each year. The agency says cases have expanded significantly since 1995, and the disease remains most common in the Northeast, mid-Atlantic and upper Midwest. That pattern makes any successful prevention tool potentially important for states such as Connecticut and Maryland, where Lyme remains a persistent concern.

Still, the reward comes with unanswered questions. Releasing gene-edited mice would require community buy-in, landowner permissions and regulatory scrutiny before any release could proceed. Ecologists will want to know how a modified trait would behave in the wild, how long it would persist and whether reducing infection in one species could create unintended effects elsewhere in the ecosystem. Ethical concerns are equally sharp: the proposal asks residents to accept a deliberate, heritable intervention in a natural population for a public-health gain that may take years to measure.

The science is advancing, but it is not starting from zero. Prior work has tested reservoir-targeted oral OspA vaccination of white-footed mice, and a 2026 Nature Communications paper reported genetically engineered Mus musculus that genomically encode a single-chain antibody against Borrelia burgdorferi. Together, those efforts suggest a plausible new prevention path. Whether it can move from a promising concept to a trustworthy tool for U.S. communities most burdened by Lyme will depend on data, regulation and public consent as much as on molecular biology.